| abstract |
The use of a compound of formula (I) or a salt, ester, amide or prodrug thereof; where X is O, or S, S(O) or S(O)2, NH or NR<12> where R<12> is hydrogen or C1-6 alkyl; R<5> is selected from a group NHC(O)OR<9>, NHC(O)R<9>, NHS(O)2R<9>, C(O)R<9>, C(O)OR<9>, S(O)R<9>, S(O)OR<9>, S(O)2OR<9>, C(O)NR<10> R<11>, S(O)NR<10>R<11> S(O)ONR<10>R<11>, where R<9>, R<10> or R<11> are various specified organic groups; R<6> is hydrogen, optionally substituted hydrocarbyl or optionally substituted heterocyclyl; R<7> and R<8> are various specified organic groups, and R<1>, R<2>, R<3>, R<4> are independently selected from halogeno, cyano, nitro, C1-3alkylsulphanyl, -N(OH)R<13>-(wherein R<7> is hydrogen, or C1-3alkyl), or R<15>X<1>-(wherein X<1> represents a direct bond, -O-, -CH2-, -OCO-, carbonyl, -S-, -SO-, -SO2-, -NR<16>CO-, -CONR<16>-, -SO2NR<16>-, -NR<17>SO2- or -NR<18>-(wherein R<16>, R<17> and R<18> each independently represents hydrogen, C1-3alkyl or C1-3alkoxy C2-3alkyl), and R<9> is hydrogen, optionally substituted hydrocarbyl, optionally substituted heterocyclyl or optionally substituted alkoxy; in the preparation of a medicament for use in the inhibition of aurora 2 kinase. |